All sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS17
PHASE 3 / 2-33
RECRUITING15
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO17%

Delay Index: of 12 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shanghai Hengrui Pharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SHR-1501
NCT05410730
P1/2RecruitingHigh-risk NMIBC1502025-05
SHR-A2102 for Injection
NCT06738251
P3RecruitingAdvanced Urothelial Carcinoma4022026-07
SHR-A2102 for Injection
NCT06512051
P1/2RecruitingAdvanced or Metastatic Non-small Cell Lung Cancer2482026-10
SHR-A2102
NCT07229729
P2RecruitingNon-small Cell Lung Cancer3002026-10
SHR-7787 injection
NCT06605222
P1/2RecruitingAdvanced Solid Tumors2012026-12 (+4 mo)
SHR-4602
NCT06704828
P2Not yet recruitingAdvanced Solid Tumors202027-04
SHR-A2102
NCT06639347
P1/2RecruitingAdvanced Urothelial Carcinoma902027-05-31
SHR-A1904
NCT06649292
P3RecruitingSecond-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma5242027-09-20
HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine
NCT07296341
P1/2RecruitingLocally Advanced or Metastatic Pancreatic Cancer With602027-10
SHR-7367 Injection
NCT07229586
P1/2RecruitingSolid Tumor1002027-12
SHR-1501, Adebrelimab
NCT07073534
P1/2RecruitingPatients With Advanced or Metastatic Malignant Tumors2032027-12
SHR-A2102
NCT06895928
P2RecruitingAdvanced Solid Tumors4002028-12
SHR-7787 Injection
NCT07268040
P2RecruitingMalignant Solid Tumors4002028-12
SHR-7787 Injection
NCT07798947
P2RecruitingLimited-stage Small-cell Lung Cancer1202028-12
SHR-9839 for Injection
NCT06474455
P1/2RecruitingAdvanced Solid Tumors1562029-06 (+36 mo)
HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
NCT07900789
P3Not yet recruitingSystemic Treatment-naïve Pancreatic Cancer8252030-11-30
SHR-A2102
NCT06417554
P1/2RecruitingAdvanced Solid Tumors802031-12-31 (+54 mo)